Less than six months after launching, Slate Medicines is already plotting to go public. The migraine-focused biotech on Monday announced plans to merge with Fulcrum Therapeutics and list on NASDAQ under the ticker "SLTE".The deal, expected to close in the fourth quarter, provides a quick exit for Fulcrum after a series of setbacks. In 2024, the biotech's muscular dystrophy drug failed in late-stage testing, dashing hopes that Fulcrum would collect any of the roughly $1 billion in milestones it was entitled to under a deal with Sanofi. Its final clinical programme, sickle cell disease hopeful pociredir, was discontinued in June following feedback from the FDA, prompting it to lay off 85% of its workforce and seek strategic alternatives. Under the transaction terms, Fulcrum stockholders are expected to own 5% of the combined company while Slate's shareholders will have a 95% stake. Fulcrum will contribute about $20.3 million in cash to the post-merger company, which will be led by Slate's CEO Gregory Oakes, and pay a cash dividend of $270 million to its stockholders.The combined company's cash, along with a concurrent $245-million private placement, are expected to fund development of Slate's two lead migraine programmes through mid-stage testing and provide runway into 2029. The financing is led by Frazier Life Sciences with participation from Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments and Mingxin Capital.Migraine portfolioSlate's most-advanced migraine asset, SLTE-1009, is a PACAP/VIP-targeting mAb engineered to have a longer half-life, enabling subcutaneous — and potentially quarterly — dosing. Slate debuted in February with a license to SLTE-1009 from Chinese firm DartsBio Pharmaceuticals and $130 million in funding.The candidate has been cleared for a Phase I healthy volunteer study in Australia, with initial safety data expected by the middle of next year. Slate's next antibody-based programme, SLTE-2100, is a bispecific directed against both PACAP/VIP and CGRP that's expected to enter the clinic in the second half of 2027. Both assets are funded through Phase II studies in migraine patients.PACAP is growing in popularity as a next-generation migraine target. Lundbeck looks to be the most advanced with bocunebart, a PACAP-targeting mAb that recently met the primary endpoint of a Phase IIb migraine study, though several others, including newly public Mentari Therapeutics and Vedana Therapeutics, both have preclinical PACAP programmes.